Juergen Froehlich

Juergen Froehlich has a strong background in the pharmaceutical industry with extensive experience in various roles. Juergen has served as the Chief Medical Officer at multiple companies, including Arcturus Therapeutics and Enbiotix Inc. At Arcturus Therapeutics, they assumed the role in 2023. Juergen has also held the position of Chief Medical Officer at Spexis AG from January 2022 to April 2023. During their time at Spexis AG, they focused on inhaled antibiotics for rare chronic respiratory infections and CXCR4 inhibitors for solid tumors and hematologic malignancy.

Before their role at Spexis AG, Juergen Froehlich was the Chief Medical Officer at Enbiotix Inc. from October 2019 to December 2021. Juergen was responsible for overseeing nonclinical and clinical development planning for various therapeutic agents. Juergen also served as the Acting Chief Medical Officer at Genevant Sciences Inc. from May 2019 to July 2020. While at Genevant Sciences, they oversaw the development of siRNA and mRNA therapeutic agents for several indications, including acromegaly, urea cycle disorders, liver fibrosis, and COVID-19 vaccine.

Prior to these positions, they held senior roles at Aradigm Corporation, Vertex Pharmaceuticals, Ipsen, Ipsen - Biomeasure, and Bristol-Myers Squibb. Notably, at Aradigm Corporation, they served as the Chief Medical Officer and Head of Regulatory Affairs. At Vertex Pharmaceuticals, they were the Vice President of Global Clinical Regulatory Strategy. At Ipsen and Ipsen - Biomeasure, they held roles such as VP Clinical and Developmental Pharmacological Sciences and Vice President of Clinical Pharmacology and North American Clinical Operations. At Bristol-Myers Squibb, they served as the Vice President of Global Medical Affairs and Vice President of Global Development and Life Cycle Management.

Overall, Juergen Froehlich has a diverse range of experience in medical and regulatory affairs, clinical development, and strategic leadership in the pharmaceutical industry.

Juergen Froehlich obtained their MD degree from the Medical School at Julius-Maximilians-Universität Würzburg, where they studied Medicine from 1978 to 1982. Later, they pursued a Master of Business Administration (MBA) degree in Business Administration at the Graduate School of Business Administration Zurich from 2001 to 2005. Additionally, it is known that they attended the Dientzenhofer Gymnasium in Bamberg, Germany, although no specific dates or degrees associated with this education are provided.